dm+d

39150611000001100

New Medicines

OtigoAcute, congestive otitis media, viral bullous otitis, and barotraumatic otitis

Information

Otigo
New formulation
Renascience Pharma
Not Known

Development and Regulatory status

Launched
None
None
November 2020
Jan 21Otigo will be available from all major wholesalers [4]
Nov 20Available in UK, Price 1 x 15ml bottle = £8.92 [1,3].
Jun 19Licensed in UK by MHRA for local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation: acute, congestive otitis media, otitis in influenza, the so called viral bullous otitis, and barotraumatic otitis. Otigo is suitable for use both in adults and children [1].

Category

Phenazone is a pyrazolone derivative with analgesic and anti-inflammatory properties. Lidocaine is a local anaesthetic from the amide group.
Otitis media (OM) occurs more in the winter than in the summer months, as it is usually associated with a cold. AOM is a particular issue in the developing world. A 2012 literature review suggested that the annual global incidence of AOM is 10.85%, comprising around 709 million cases per year, about half in under-5s. Incidence varies by a factor of ten or more between high-income and low-income countries [1].
Acute, congestive otitis media, viral bullous otitis, and barotraumatic otitis
Topical

Evidence based evaluations

11 February 2021AWMSG